Active Heymann nephritis in complement component C6 deficient rats  by Leenaerts, Peter L. et al.
Kidney International, Vol. 47 (1995), PP. 1604—1614
Active Heymann nephritis in complement component C6
deficient rats
PETER L. LEENAERTS, BRUCE M. HALL, BOUDEWIJN J. VAN DAMME, MOHAMED R. D,
and YVES F. VANRENTERGHEM
Departments of Nephrology and Pathology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium; Department of Medicine, University
of New South Wales, Liverpool Hospital, Liverpool, N S W Australia; and Department of Nephrology, University of Leiden, Leiden, The Netherlands
Active Heymann nephritis in complement component C6 deficient rats.
The mechanisms of renal injury that result in proteinuria in active
Heymann nephritis (AHN) remain unclear, though data suggest that in
analogy of the passive form of the disease the membrane attack complex
C5b-9 may be involved. AHN was induced in an inbred strain of PVG/c
rats that are totally deficient in the C6 component of complement and are
unable to form the lytic C5b-9 complex, as well as in non-complement
deficient PVG/c rats that are immunologic identical to the deficient
strain. In both groups of animals comparably high titers of anti-Fx1A
autoantibodies were found after three weeks and persisted at 40 weeks.
Proteinuria was also similar in both groups, and was first evident at six
weeks. High levels of urinary protein, ranging from 200 mg124 hr to 500
mg124 hr, were found after 10 weeks and persisted up to one year. Renal
biopsy findings at various times post-immunization were identical in both
groups, including immunofluoresence staining for Ig and C3 deposits, and
also EM findings of subepithelial electron-dense deposits were not
different. The injection of heterologous rabbit complement, that partially
and temporarily restored the CH50 activity in PVG/c rats did not alter or
hasten the disease. Long-term follow-up showed that all rats in both
groups continued to have severe proteinuria and that most animals died
between 8 to 12 months after disease induction, without renal impairment.
EM findings in serial biopsies demonstrated that the growth of the
subepithelial deposits as measured by surface area occurred between
weeks 4 and 12. A positive correlation (r = 0.94) between the size of the
deposits and the level of proteinuria was found. These studies demon-
strate that the membrane attack complex of complement does not play a
major role in AHN. The relationship of the size of the immune deposits to
the level of proteinuria suggests that the growth of the immune deposits
on itself initiate secondary mechanisms that damage the permselective
characteristics of the glomerular membrane.
Active Heymann nephritis (AHN) was first reported in 1959 as
an experimental model of human membranous nephropathy that
was induced by immunization of rats with homologous kidney
homogenate in complete Freund adjuvant [1]. Later studies
showed that the responsible nephritogenic antigens present in the
homogenate were of renal tubular origin [2—4]. The disease is
characterized by the appearance of autoantibodies and the for-
mation of subepithelial electron-dense deposits after two to three
weeks. Frank proteinuria is seen within two months of immuni-
zation. In contrast to passive Heymann nephritis (PHN) that is
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rapidly obtained by administration of heterologous antibody to
the homogenate Fx1A, AHN is a true autoimmune disease with a
slow evolution [5].
The discovery that the pathogenesis of Heymann nephritis
(HN) was not caused by circulating immune complexes but by in
situ binding of antibodies to intrinsic epithelial antigens and local
formation of deposits was an important step in unraveling the
disease mechanisms of this experimental model [6—8]. This
finding showed that glomerular membrane damage was not
caused by passage of immune complexes. Salant and colleagues
later hypothesized that the terminal components of complement
unified in the membrane attack complex (MAC) C5b-9 were
responsible for the early damage of the glomerular membrane in
PHN [9]. Since then, several reports have highlighted the role of
the C5b-9 complex in membranous nephropathy [reviewed in 5,
10, 11].
Due to the variability of the disease and the inability to
decomplement the rats over a long time period it has never been
shown that proteinuria is also complement mediated in AHN [5].
Nevertheless, indirect evidence is available that complement also
plays a role in AHN [12] and even in other forms of human
glomerulonephritis [13, 14].
We have recently discovered a colony of PVG/c rats totally
deficient in component C6 and unable to form a functional C5b-9
complex as measured by its inability to lyse sensitized sheep RBC
[15]. These rats were designated PVG/c. All other colonies of
PVG/c rats showed normal complement activity. One of these,
designated PVG/c, was found to be immunologically identical to
the PVG/c rat [15].
To investigate whether the absence of functional C5b-9 com-
plex was of significance for the development and evolution of
AHN we induced the disease in PVG/c and PVG/c rats.
Methods
Animal models
Inbred male and female PVG/c and C6 deficient PVG/c rats
eight to nine weeks old and weighting between 160 and 220 g were
used in all experiments. PVG/c rats were obtained from B&K
Universal Ltd. (Hull, UK). PVG/c rats were bred in our own
animal facilities. The characteristics of these rats have been
described elsewhere [15].
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Fig. 1. Example of measuring the size of immune deposits by measuring the surface area with a planimeter. Only the three largest deposits of five randomly
chosen capillary loops of five randomly chosen glomeruli per biopsy were measured. Magnification was 10,000X. The encircled deposit (arrow)
measured 0.47 jm2.
Rats were maintained on standard chow and water ad libitum. Monitoring of active Heymann nephritis
During 24-hour urine collections rats were deprived of chow.
AHN was induced by a single injection in the left hind food pad Twenty-four hour urine samples collected in metabolic cages
of 15 mg of brush border antigens Fx1A, prepared as described were assayed for protein by the biuret method. Blood was
16] and dissolved in 0.15 ml complete Freund adjuvant contain- obtained from the lateral vein of the tail of rats anesthetized with
ing Mycobacterium tuberculosis HRa37 (Difco, Detroit, MI, ether. Serum was stored at —80°C until further assayed for
USA). No booster vaccination was administered. autoantibody titer, serum creatinine and functional complement.
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Fig. 2. Anti-FxJA autoantibody titers of PVG/c (—Ii—) and PVG!c(———). The number of animals were ten and nine, respectively. The
ordinate represents the reciprocal of the dilutions on a log2 scale. Values
are means SD.
Anti-Fx1A autoantibody titers were determined by ELISA as
described [17]. Briefly, microtiter plates (NUNC, Roskilde, Den-
mark) were coated overnight with 1 j.tg of Fx1A in 0,1 ml PBS.
Plates were washed three times with PBST (PBS with 0.05%
Tween 20) and blocked with 2% bovine serum albumin (BSA) for
one hour at room temperature followed by two washes. Diluted
rat sera were added to the plates for one hour at 37°C. A dilution
series of strong positive and negative sera were used as references.
After three washes the plates were incubated at 37°C with goat
anti-rat Ig alkaline phosphatase (Caltag, San Francisco, CA,
USA) diluted 1/500 in BSA 2% and washed again three times with
PBST and once with carbonate-bicarbonate buffer. Finally, 0.1 ml
0.5% p-nitrophenyl phosphate (Sigma, St. Louis, MO, USA) was
added for 15 minutes. The yellow color reaction was read at 405
nm on an ELISA reader. The titer was determined as the
reciprocal of the last dilution that differed significantly from
negative serum. Arbitrarily, the level of positivity was determined
as the mean value of absorbance of the diluted negative serum
augmented with two standard deviations.
Serum creatinine was measured with a standard photocolori-
metric method on samples previously depleted of lipids by ultra-
centrifugation at 46,000 X g.
Lytic activity of complement was monitored with the CH5O
assay [17, 18]. Briefly, sheep red blood cells (SRBC) were first
sensitized with decomplemented rabbit anti-SRBC serum to
become activated erythrocytes (EA). Hemolysis was measured by
reading the optical density of the supernatants at 541 nm. The
reciprocal of the serum dilution that resulted in 50% hemolysis is
defined as the CH5O value expressed in units per ml. A control
serum containing 52 CH5O units per ml (Sigma) was used as a
standard.
Kidney biopsies were taken by a surgical procedure with partial
resection of the cortex of the lower pole of the left kidney. Up to
three biopsies were taken in the same animal during the follow-up
period. Part of the tissue was snap frozen in liquid nitrogen and
stored at —80°C for immunofluorescence studies. Another part of
the tissue was fixed in glutaraldehyde 4% in PBS for electron
microscopy (EM).
Immunofluorescent staining of frozen biopsies was performed
with rabbit anti-rat Ig and with FITC conjugated anti-rat C3, both
prepared in the laboratory of one of us (M.D.). The intensity of
the granular deposits was scored as reported [19]. EM was done to
assess immune deposit size at various stages of the disease. The
size of the immune deposits was related to the time post-
immunization and the level of proteinuria. Photomicrographs
with a magnification of 10,000 X were taken of five randomly
chosen capillary loops of a particular glomerulus. Of each biopsy
five randomly chosen capillary loops were investigated. The
surface area of the three largest immune deposits observed in
each biopsy was measured with a planimeter that was accurate up
to 10 mm2 (Haff, Pfronten, Germany) or, taken into account the
magnification in the microscope and in the photographic print, up
to 0.02 im2 (Fig. 1). The reasoning behind this strategy was that
several investigators have claimed that the C5b-9 complex is
demonstrable in the deposits and this complex might have caused
a substantial growth of the deposits as its size is several million
Daltons. It was not excluded that part of the disease was deter-
mined by the size of the deposits. In general, more than thirty
deposits were demonstrable in five capillary loops per biopsy. The
foregoing methodology is also a quantitative method to measure
the size of the deposits. Indeed, to quantitavely determine the size
of the deposits from the two-dimensional photographs two ques-
tions have to be resolved. First, what is the distribution of the size
of the deposits and second how to determine the size of the
deposits from the sections seen on the photographs. Starting with
the latter, if all deposits have equal size and showed a spherical
configuration then it will be clear that the largest two-dimensional
deposit will be a section through the equator plane of the deposit.
The cross sectional areas of the deposits are related to the cosinus
fuction, for example a section at 20° from the equator has a
surface area of r(Radiusequator cos 20)2. This is more than 88%
of the surface area of the equator plane. Thus, any section within
the range 20° of the equator plane closely represents the size of
the deposit. The frequency of random cross sections of the sfere
are represented by the sinus function, for example, the probability
to find a section between the equator plane and the plane at 20°
is given by sinus 20° which is 34%. Using the binomial distribution
it can be shown that the probability to find at least 3 out of 30
deposits within the 34% interval is more than 98%. Thus, the
mean value of the three largest two-dimensional deposits is a good
estimation for the equator plane. The foregoing reasoning is by
approximation still valid when a disc-shaped configuration for the
deposits is assumed. This configuration with the long axis twice
the short axis ressembles much more the real two-dimensional
sections. If the size of the deposits is gaussian distributed with a
small standard deviation then the foregoing is an accurate deter-
mination of the size of the deposits. From three biopsies we
measured all two-dimensional deposits and found in all three that,
when we ranked the surface areas from each biopsy from small to
large, about 50% of the deposits showed a surface area of 75% or
more of the largest surface area. Such a distribution ressembles
the sinus and cosinus function of above [sinus 30° = 0.5; (cosinus
30)2 = 0.75]. This finding implicates that the gaussian distribu-
tion must be narrow. With other words all deposits develop in an
equal way and reach sizes that do not differ much to each other.
Taken together, measuring the three largest two-dimensional
deposits out of a series of more than thirty gives a good estimation
of the magnitude of the deposits. The method has the advantages
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Fig. 3. Immunofluorescence staining for rat Ig (A) and rat C3 (B) at four weeks after induction 0fAHN in a Pl/G1c rat. Staining intensities did not differ
to those of non-complement deficient rats.
EC
a)0
Week 4 Week 8 Week 12 Week 20 Week 40
Proteinuria mg/day
PVG/c*
Males 12.2 3.1 (10) 112 54(10) 231 68(10) 276 90(5) 344 102 (3)
Females 2.7 1.6 (10) 44 37 (10) 129 42(10) 188 68(5) 174 46(4)
PVG/c
Males 14.4 4.9 (10) 214 106 (9) 328 86 (9) 312 72 (5) 412 67 (2)
Females 3.2 1.4 (10) 52 27 (10) 154 54(10) 235 74(5) 248 88(4)
Creatinine mg/dl
PVG/c 0.36 0.04 (20) 0.42 0.05 (20) 0.47 0.08 (20) 0.44 0.07 (10) 0.68 0.09 (7)
PVG/c 0.34 0.05 (20)
-
0.39 0.05 (19) 0.49 0.08 (19) 0.52 0.10 (10) 0.74 0.12 (6)
Males and females are separately represented for proteinuria. The values are means SD. Values between parentheses are number of rats involved.
None of the animals at any time point showed a level of serum creatinine of more than 1 mg/dl. At week 12 the first ten rats of each group were
eliminated.
8
animals of each group were used to monitor AHN during the first
three months, whereafter these animals were sacrificed as repet-
itive biopsies might have impaired the natural evolution of their
renal function. From these rats blood was drawn at regular time
intervals and biopsies were taken monthly during the first three
months. The other ten rats of each group were used for long-term
follow-up and were further monitored from month three until
natural death or for one year. During this period repetitive
biopsies were taken in some rats.
In a second series of experiments AHN was induced in two
groups of animals each containing six male PVG/c rats. The first
group was the control group. The rats of the second group were
injected i.v. with 1 ml of heterologous rabbit complement at week
three after AHN induction when autoantibodies were present in
serum and glomeruli but rats did not yet show proteinuria. The
evolution of the two groups of animals was monitored.
than determining the mean value of all two-dimensional deposits.
Statistics
Expenmental design
AL-IN was induced in two groups of PVG/c and PVG/c rats, Statistical calculations were performed using the Mann-Whit-
each containing ten male and ten female animals. Proteinuria was ney non-paired tests for proteinuria and the Student's t-test for
determined in all animals at regular time intervals. The first ten serum autoantibody and serum creatinine. Linear regression was
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Fig. 4. Proteinuria of 24 hours of the first ten rats of each group at days (B) 0, (B) 28, (1) 42, and (•) 56. Male M3 of the PVG/c group died during
surgery at four weeks. Females F2 and F3 of the same group showed 14 and 17 mg per day of proteinuria at 56 days, respectively. This is significantly
different to non-induced females (less then 5 mg per day). By week twelve their urinary protein loss had increased to 48 and 86 mg per day, respectively.
Table 1. Evolution of proteinuria and serum creatinine
Ml M2 M3 M4 M5 Fl F2 F3 F4 F5 Ml M2 M3 M4 M5 Fl F2 F3 F4 F5
Table 2. CH5O in complement reconstituted PVG/c rats
Rat Day 1 Day 2 Day 8
1 46 30
2 26 22
3 30 20
4 42 18 <5
5 22 10 <5
6 30 10 <5
CFI5O is expressed in U/mI and represents the reciprocal of the dilution
that causes 50% hemolysis of antibody-coated sheep RBC. The CH5O
value of normal PVG/c serum and rabbit serum was measured 84 U/mI
and 110 U/mI, respectively. At day 8 most animals showed no detectable
CT 150 value. At day 15 (not shown), CH5O was demonstrable in none of
the six rats.
of being less time consuming and more accurate in absolute values
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Fig. 5. Administration of heterologous rabbit complement does not alter the
disease evolution in PVG/c rats. Autoantibody titers (circles) and protein-
uria (bars) are represented for two groups of male PVG/c rats (N = 6)
ofwhich one was not reconstituted (closed symbols) and the other group
(open symbols) was injected with one ml of fresh rabbit serum. Values are
means SD. Figures between parenthesis represent mean proteinuria.
done between size of immune deposits and level of proteinuria.
P < 0.05 was considered a significant difference.
Results
Autoantibody production and immunofluorescent studies
Both PVG/c and PVG!c rats rapidly raised anti-Fx1A anti-
bodies as shown in Figure 2. Antibodies started to appear after
one week and reached high levels at week three whereafter the
titers remained invariably high throughout the lifespan of the rats.
No difference was seen in titer between the two rat colonies at any
time point.
Similar results were obtained when biopsies were stained for rat
Ig and rat C3 (Fig. 3). At week four, fine granular immunofluo-
rescence of equal intensity was observed in both PVG/c and
PVG/c rats.
Proteinuria
Basal proteinuria in both rat colonies matched each other.
Males showed levels between 5 mg/day and 12 mg/day, whereas
the basal urinary protein loss in females always was less than 5
mg/day. Unmanipulated rats did not develop disease and did not
show an increase in basal proteinuria by aging. After induction of
Al-IN the rats remained free of proteinuria during the first four
weeks. At week six several animals showed significant levels of
proteinuria and by week eight the majority to these rats became
severely proteinuric showing protein losses of more than 100
mg/day. Figure 4 represents the individual values of proteinuria
during the first eight weeks of the first ten rats of each group.
Though variable levels were measured all rats developed marked
proteinuria. No clear difference was seen between PVG/c and
PVG/c rats. Females tended to develop proteinuria a little later
and to a little lesser extent that males (Table 1). Once the rats
showed severe proteinuria they continued to have high levels of
urinary protein loss during their lifespan. Proteinuria of more
than 0.4 g/day, turning the sera of lipids milky, was common. As
expected, edema was not observed in these animals [20].
Reconstitution with heterologous complement
Apparently both rat colonies developed proteinuria, but as
proteinuria was only determined every two and four weeks
PVG/c rats could have developed the disease a little earlier than
the complement deficient ones. Though in this case the mecha-
nism of renal injury could not solely be attributed to the C5b-9
complex, it still might contribute to the development of the
disease. Also, regarding homologous restriction of complement
[21], where homologous cells are at least partially protected
against homologous complement, it was meaningful to reconsti-
tute the complement deficient rats with heterologous rabbit
complement at the time anti-Fx1A antibodies were present and
yet no significant proteinuria had developed. We reasoned that, if
in this case no influence was seen on the evolution of the disease,
it would definitely have been shown that the C5b-9 complex
played no role in AHN. Two groups of PVG/c rats were induced
with AHN. One of them was injected with 1 ml of rabbit serum at
week three, when anti-Fx1A antibodies were present. Hemolytic
activity was partially and temporarily reconstituted as shown in
Table 2. Nevertheless, the development of proteinuria was not
accelerated nor was an increase in the levels of proteinuria
observed demonstrating that administration of heterologous com-
plement with reconstitution of hemolytic activity had no influence
in AHN (Fig. 5).
Ultrastructural studies
In AHN, proteinuria develops six weeks after induction, where-
after levels of proteinuria of several hundred mg per day are
reached within four to six weeks. To answer the question of what
happens during this time period sequential biopsies were taken in
several rats. In all animals a marked increase of the size of the
deposits was observed over time (Fig. 6). Also, large deposits
caused detachment of the glomerular epithelial cells and distor-
tion of the slit pore membranes. Simultaneously with the increases
of the size of the complexes an increase in proteinuria was found.
Figure 7 shows the relationship between the size of the three
largest deposits found in the biopsy and proteinuria. Small
deposits, present at four weeks after induction, had not caused
significant proteinuria. Between a surface area of 0.20 and 1.20
rm2 of the deposits a fairly linear relationship between size of the
deposits and proteinuria was found. These data were obtained
from biopsies taken six to twelve weeks after induction. Later
biopsies and some biopsies taken at twelve weeks are represented
in area 3. A clear linear relationship is no longer present. The
maximal size of the deposits seems limited to 2.0 m2. After more
than twelve weeks neither the size of the deposits nor the
proteinuria changed for the individual rat (not shown). Thus,
before protein uria develops, a minimal size of the deposits has to
he reached. Further growth over time results in an increase in
proteinuria.
Long term follow-up
Table 1 shows the evolution of proteinuria and serum creatinine
of PVG/c and PVG/c rats. All rats developed comparable
levels of proteinuria while no rats developed severe renal insuffi-
ciency. The small rise in serum creatinine can at least partially be
explained by the repetitive biopsies which caused loss of kidney
mass. The survival graph is represented in Figure 8. A major
number of rats died between weeks 36 and 52 while non-diseased
rats live for more than two years (not shown). The cause of death
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Fig. 6. EMfindings in PVG/c rat M5 at four (A), six (B) and eight (C) weeks after induction of AHN. Proteinurias were 12 mg per day, 25 mg per day
and 188 mg per day, respectively. Notice the marked increase of the size of the immune deposits and the flattening of the glomerular epithelial cells
(arrows). Magnification was 10,000 x.
is not immediately clear and does not seem to be related to
impaired renal function. Though not investigated, thrombotic
accidents maybe a plausible explanation for sudden death in these
nephrotic animals.
However, no difference was observed between deficient and
normal rats, which shows that C6 deficiency had no influence on
the natural evolution of the nephrotic rats.
Discussion
The mechanisms of renal injury in AHN have not been
conclusively resolved. By analogy to PHN it was assumed that
complement, and more particularly the MAC, which is composed
of the C5b-9, was responsible for mediating glomerular injury that
results in proteinuria [10—12]. This contention was supported by
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Fig. 6. Continued.
the finding of C5b-9 complex in electron dense deposits in
biopsies of AHN [12]. The chance discovery of a C6 deficient rat
provided an opportunity to examine whether the C5b-9 MAC was
essential for the induction of glomerular injury and its resultant
proteinuria in AHN. In this study we compared PVG rats
deficient in the C6 component of complement to PVG rats with
normal complement components which were immunologically
identical. As would be expected the immune response to the
immunization with Fx1A was identical in both groups of rats. High
titers of autoantibodies were observed by three weeks post-
immunisation, and there was evidence of equal deposition of
autoantibody and C3 in the glomeruli of complement deficient
and normal rats at four weeks post-immunization. Surprisingly
there was no difference in the time course and the severity of the
proteinuria in both groups of rats. This suggests that the MAC is
not essential in inducing the glomerular injury which causes
proteinuria in AHN. To examine whether there was a small
difference in the onset of proteinuria or whether repletion of the
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Fig. 6. Continued.
complement cascade would accelerate the disease, we undertook
experiments where rats were reconstituted with rabbit serum at
three weeks post-immunization. At this time they had high
anti-Fx1A titers and Ig and C3 in their glomeruli. Although the
complement cascade was partially restored as measured by the
CH5O assay the evolution of the disease was not changed at all.
Taken together, these findings demonstrate that the C5b-9
complex does not play a role in AHN. The role of complement in
models of nephritis has for technical reasons only been studied in
acute models. This is due to the lack of rodents with established
complement deficiencies and because depletion of complement
factors is limited in time. Therefore, studies identifying a role for
complement have used the passive form of HN [9—111. In this
model a heterologous phase followed by an autologous phase
results in proteinuria and urinary C5b-9 loss within a few days
after the administration of the heterologous antibodies [22].
While in PHN the whole process of glomerular membrane
damage occurs within ten days, in the AHN model it takes at least
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Fig. 7. Relationship between size of the largest immune deposits of randomly
chosen capillaty loops and proteinuria. Small deposits (area 1), observed at
four weeks after induction of the disease, were not associated with
significant proteinuria. A linear correlation (r = 0.94) was found from a
size of 0.16 to 0.20 to 1.20 jim2 (area 2). In nearly all animals these data
points were obtained from biopsies taken between six and twelve weeks
after disease induction. Later biopsies (area 3) showed large deposits of
1.30 to 2.00 jim2 with a lesser correlation with proteinuria. Squares
represent PVG/c rats, crosses PVG/c rats.
six weeks before the development of proteinuria. This is despite
the fact that in AHN high titers of autoantibody develop within
three weeks of immunization and intraglomerular Ig, C3 and
electron dense deposits are observed by four weeks. Why the
C5b-9 complex only takes a few days to damage the glomerular
membrane in PHN and several weeks in ARN has never been
explained. That the C5b-9 complex is not critical for glomerular
injury is not surprising since there is increasing evidence that this
pathway may not be that relevant to the mediation of damage to
nucleated cells in vivo. Not only are nucleated cells extremely
resistant to complement damage [23, 241, they are also protected
against homologous complement by membrane bound factors as
CD59, decay accelerating factor (DAF) and others [21]. These
factors tend to be specific in deactivating homologous comple-
ment. They are less resistant to heterologous complement. Nev-
ertheless, our experiments demonstrated that even heterologous
complement had no influence.
Our findings do not completely rule out a role of complement,
however. The deficient rats showed early deposition of C3 which
could not be distinguished from the amount of C3 found in the
glomeruli of normal rats. It is not excluded that complement by
release of chemotactic factors in both groups of animals may have
contributed to glomerular injury [251. Other studies have also
demonstrated that antibody without complement activation can
mediate glomerular injury. These include the infusion of mono-
clonal antibodies specific to glomerular antigens which do not fix
complement but can induce glomerular injury and proteinuria [26,
27]. Further, in anti-GBM nephritis in guinea pigs decomplemen-
tation does not prevent glomerular injury [28]. In humans, indi-
viduals with complement pathway defects are prone to nephritis
and not protected from it [291.
If the C5b-9 complex does not play the key role in AHN we
20
Time, weeks
Fig. 8. Long-term survival curves often PVG/c (--) and PVG/c (—) rats.
All animals showed severe proteinuria (range from 148 mg to 570 mg per
day) which did not change substantially within the follow-up period.
wondered which other mechanisms cause the renal injury. We
demonstrated that deposition of immunoglobulin and activation
of the early components of complement did not immediately
result in proteinuria. We therefore examined whether the form or
size of the immune complexes were related to the onset of
proteinuria. Earlier reports on other forms of experimental
glomerulonephritis have focused on ultrastructural alterations
during disease induction [30, 31]. Changes in the integrity of the
slit pore membrane and detachment of glomerular epithelial cells
seems to be related to the appearance or increase of proteinuria.
Other parameters such as detachment, distortion of the slit pore
membrane, localization of the deposit, length and size of the
deposit and others may all influence the integrity of the glomer-
ular membrane. A study of all these parameters and their
contribution to glomerular membrane damage would require a
large amount of EM biopsies and computerized planimetry. We
limited our study to measuring the largest deposits in the two-
dimensional plane of the EM photograph. It was found that
deposits gradually increase in size and that simultaneously pro-
teinuria appeared. Small deposits did not cause significant pro-
teinuria. It seems that a minimal size is necessary to cause
proteinuria. Further increase results in concomitant increase in
proteinuria. Immune deposits reach their maximal size approxi-
mately twelve weeks after disease induction and remain virtually
unchanged during the life span of the rats. The same is true for
proteinuria. When immune deposits are relatively small, some
form of slow endocytosis occurs, as has been shown by others
[32—34]. This is in contrast to immune complexes at the capillary
side of the basal membrane which are rapidly cleared [351.Once
a maximal size of the deposits has been reached, an equilibrium
between growth and clearance exists or, and essentially not
different, circulating autoantibodies hardly find nephritogenic
antigens when large deposits are formed.
These data lead us to a picture of AHN of a true autoimmune
disease with a slow progressive growth of immune deposits and a
concomitant appearance of proteinuria. In contrast to models
with monoclonal antibodies [26, 27, 36] AHN is not a model of
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glomerulonephritis in which apparently crucial membrane struc-
tures are damaged which result in immediate proteinuria. Thus,
the logical conclusion of the above is that a pure mechanistic
theory explains the renal injury in AHN. Immune deposits
damage the glomerular membrane and cause proteinuria by virtue
of their size. Secondary mechanisms such as flattening and
detachment of glomerular epithelial cells and distortion of slit
pore membranes are the result of the growth of the immune
deposits. These mechanisms are probably much more relevant for
the proteinuria than size of the deposits on itself. More recently,
similar data have been reported in human membranous nephrop-
athy [371. Insofar as AHN reflects human membranous nephrop-
athy, these ideas might have important implications for its treat-
ment.
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